Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.38 |
| ▸ | WNT3A | P56704 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17341957 | 0.93 | KDM4E (0.34) | KDM4EHPGDSMN1; SMN2CTNNB1WNT3A | |
| SCHEMBL17341968 | 0.92 | FAAH (0.35) | KDM4EHPGDSMN1; SMN2CTNNB1WNT3A | |
| SCHEMBL17345607 | 0.89 | KMT2A (0.48) | KDM4EHPGDCTNNB1WNT3AALDH1A1 | |
| SCHEMBL17345608 | 0.84 | KMT2A (0.40) | KDM4EHPGDALDH1A1CYP1A2GLA | |
| SCHEMBL17341963 | 0.83 | KMT2A (0.40) | KDM4EHPGDALDH1A1CYP1A2GLA | |
| SCHEMBL17341961 | 0.83 | CTNNB1 (0.45) | KDM4EHPGDSMN1; SMN2CTNNB1WNT3A | |
| SCHEMBL17341962 | 0.77 | HTT (0.35) | SMN1; SMN2ALDH1A1POLBKMT2A | |
| SCHEMBL19821107 | 0.76 | CTNNB1 (0.41) | KDM4EHPGDSMN1; SMN2CTNNB1WNT3A | |
| SCHEMBL17341960 | 0.75 | IAPP (0.35) | ALDH1A1KMT2A | |
| SCHEMBL17341972 | 0.75 | CTNNB1 (0.40) | KDM4EHPGDSMN1; SMN2CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180029990-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-01 | — | — | US | disclosed |
| US-9790186-B2 | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2017-10-17 | — | — | US | disclosed |
| US-20150361045-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361045-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | FABP2, LRBA, VIP | KDM4E 4697/4885HPGD 1026/4885SMN1; SMN2 4679/4885 |
| US-20180029990-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | FABP2, LRBA, VIP | KDM4E 4697/4885HPGD 1026/4885SMN1; SMN2 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.